Bridging patients in cardiogenic shock with a paracorporeal pulsatile biventricular assist device to heart transplantation-a single-centre experience.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
24 03 2022
Historique:
received: 24 05 2021
revised: 06 09 2021
accepted: 14 11 2021
pubmed: 13 1 2022
medline: 8 4 2022
entrez: 12 1 2022
Statut: ppublish

Résumé

We evaluated the outcome of patients in cardiogenic shock receiving a paracorporeal pulsatile biventricular assist device as a bridge to transplantation. We performed a retrospective single-centre analysis of all patients who received a Berlin Heart Excor® at our institution between 2004 and 2019. A total of 97 patients (90 adults, 7 paediatric) were analysed. Eighty-four patients were in Interagency Registry for Mechanically Assisted Circulatory Support level 1 (80 adults, 4 paediatric). Diagnoses were dilated cardiomyopathy (n = 41), ischaemic cardiomyopathy (n = 17) or myocardial infarction (n = 4), myocarditis (n = 15), restrictive cardiomyopathy (n = 2), graft failure after heart transplant (n = 7), postcardiotomy heart failure (n = 5), postpartum cardiomyopathy (n = 3), congenital heart disease (n = 1), valvular cardiomyopathy (n = 1) and toxic cardiomyopathy (n = 1). All patients were in biventricular heart failure and had secondary organ dysfunction. The mean duration of support was 63 days (0-487 days). There was a significant decrease in creatinine values after assist device implantation (from 1.83 ± 0.79 to 1.12 ± 0.67 mg/dl, P = 0.001) as well as a decrease in bilirubin values (from 3.94 ± 4.58 to 2.65 ± 3.61 mg/dl, P = 0.084). Cerebral stroke occurred in 16 patients, bleeding in 15 and infection in 13 patients. Forty-eight patients died on support, while 49 patients could be successfully bridged to transplantation. Thirty-day survival and 1-year survival were 70.1% and 41.2%, respectively. A pulsatile biventricular assist device is a reasonable therapeutic option in cardiogenic shock, when immediate high cardiac output is necessary to rescue the already impaired kidney and liver function of the patient.

Identifiants

pubmed: 35020902
pii: 6502514
doi: 10.1093/ejcts/ezab547
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

942-949

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Sebastian Michel (S)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.
Division of Congenital Heart Surgery, Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Stefan Buchholz (S)

MediClin Heart Center, Lahr, Germany.

Joscha Buech (J)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Tobias Veit (T)

Department of Pulmonology, Ludwig Maximilian University Munich, Munich, Germany.

Thomas Fabry (T)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Jan Abicht (J)

Department of Anesthesiology, Ludwig Maximilian University Munich, Munich, Germany.

Nikolaus Thierfelder (N)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Christoph Mueller (C)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Laura Lily Rosenthal (LL)

Division of Congenital Heart Surgery, Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Jelena Pabst von Ohain (J)

Division of Congenital Heart Surgery, Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Nikolaus Haas (N)

Department of Pediatric Cardiology, Ludwig Maximilian University Munich, Munich, Germany.

Jürgen Hörer (J)

Division of Congenital Heart Surgery, Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.

Christian Hagl (C)

Department of Cardiac Surgery, Ludwig Maximilian University Munich, Munich, Germany.
Munich Heart Alliance, German Centre for Cardiovascular Research, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH